Related Experiment Video
Updated: May 19, 2026
08:11
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
Published on: November 14, 2016
Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS
Robert J Fox1, Alan Thompson, David Baker
1Mellen Center for Multiple Sclerosis, Neurological Institute, and Lerner College of Medicine, Cleveland Clinic, Cleveland, OH 44122, USA.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|August 25, 2012
Summary
Developing effective treatments for progressive multiple sclerosis (MS) requires addressing key research challenges. An integrated, multi-disciplinary approach is crucial for expediting new therapies for progressive MS.
Area of Science:
- Neurology
- Immunology
- Therapeutics Development
Background:
- Relapsing forms of multiple sclerosis (MS) have seen therapeutic advancements, but progressive MS treatments remain limited.
- Progressive MS presents unique challenges in disease modification and symptom management.
Purpose of the Study:
- To review current challenges in developing therapies for progressive MS.
- To identify and prioritize key research areas for advancing progressive MS treatments.
Main Methods:
- Convened a collaborative of MS society leaders and researchers.
- Conducted scientific and strategic planning meetings to identify research priorities.
- Focused on five key areas: experimental models, target identification/validation, clinical trial strategies, outcome measures, and symptom management.
Main Results:
- Identified five critical priority areas for progressive MS research.
- Emphasized the need for novel experimental models and validated therapeutic targets.
- Highlighted the importance of refined clinical trial designs and outcome measures.
Conclusions:
- An integrated, multi-disciplinary approach is essential to overcome impediments in progressive MS therapy development.
- International collaboration and dedicated funding are necessary to expedite research and translate findings into effective treatments.
- The ultimate goal is to accelerate the development of disease-modifying and symptom-relief therapies for progressive MS.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:21EPS and iPS Cells in Disease Research
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...